Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The objective of the OPTIMAL study is to demonstrate that the adjunction of Maraviroc to a
combination of antiretroviral therapy in naive and late diagnosed HIV-1 infected patients
counts may accelerate the kinetics of immune restoration and decrease the risk of disease
progression and death.
It is a randomized, versus placebo, double-blind trial, conducted in France, Spain and Italy.
Phase:
Phase 3
Details
Lead Sponsor:
ANRS, Emerging Infectious Diseases French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)